{"id":2691,"date":"2026-02-18T09:45:14","date_gmt":"2026-02-18T09:45:14","guid":{"rendered":"https:\/\/helsinn.com\/?p=2691"},"modified":"2026-04-16T09:16:24","modified_gmt":"2026-04-16T08:16:24","slug":"helsinn-announces-european-commission-approval-of-akynzeo-oral-suspension","status":"publish","type":"post","link":"https:\/\/helsinn.com\/en_us\/news\/helsinn-announces-european-commission-approval-of-akynzeo-oral-suspension\/","title":{"rendered":"Helsinn announces European Commission approval of AKYNZEO\u00ae Oral Suspension"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Lugano, Switzerland \u2013 February 18th, 2026 \u2013 <\/strong>Helsinn Healthcare SA (\u201cHelsinn\u201d), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the European Commission (EC) has granted marketing authorization for the new oral suspension formulation of AKYNZEO\u00ae<\/sup> (netupitant\/palonosetron) on 12th<\/sup> of February 2026.<\/p>\n

This approval marks a significant milestone in the expansion of the AKYNZEO\u00ae<\/sup> portfolio, offering a new therapeutic option alongside the currently approved formulations. The oral suspension is designed to provide additional flexibility and benefits to cancer patients, including those who may have difficulty swallowing.<\/p>\n

Following the EC decision, the commercial launch of the AKYNZEO\u00ae<\/sup> oral suspension in Europe is anticipated in the coming months.<\/p>\n

Roberta Cannella, Chief Operating Officer of Helsinn,<\/strong> commented: <\/strong>\u201cWe are proud that the European Commission has approved the new oral suspension formulation of AKYNZEO\u00ae<\/sup>. The authorization of this innovative formulation reflects our longstanding commitment to advancing supportive cancer care. With this new addition to the AKYNZEO\u00ae<\/sup> portfolio, we take another meaningful step toward improving the daily lives of patients undergoing cancer treatment.\u201d<\/p>\n

<\/p>\n

<\/p>\n

\nAbout AKYNZEO\u00ae<\/strong><\/summary>\n

<\/p>\n

AKYNZEO\u00ae<\/sup> is a 5-HT3\u00a0and NK1\u00a0receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.<\/p>\n

For additional information please see the EU Summary of Product Characteristics<\/u><\/a>.<\/p>\n

<\/p>\n<\/details>\n

<\/p>\n

<\/p>\n

\nAbout Helsinn<\/strong><\/summary>\n

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China, and a network of trusted partners enabling a commercial presence in 90 countries.<\/p>\n

Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. For half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously fosters innovation for its patients and embraces sustainable growth as a core element of its strategic vision.<\/p>\n

To learn more about Helsinn, please visit www.helsinn.com<\/a> or follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n<\/details>\n

\u00a0<\/p>\n

Download the PR here<\/strong><\/a><\/p>\n

\n
\n

<\/p>\n

<\/p>\n

\u00a0<\/p>\n

\n

<\/p>\n<\/div>\n

<\/p>\n<\/blockquote>\n

<\/p>\n<\/blockquote>\n

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>","protected":false},"author":5,"featured_media":440,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[18],"class_list":["post-2691","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-cycle-development","tag-featured-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/posts\/2691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/comments?post=2691"}],"version-history":[{"count":13,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/posts\/2691\/revisions"}],"predecessor-version":[{"id":3141,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/posts\/2691\/revisions\/3141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/media\/440"}],"wp:attachment":[{"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/media?parent=2691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/categories?post=2691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helsinn.com\/en_us\/wp-json\/wp\/v2\/tags?post=2691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}